Investors in biotech stocks Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) and Medivation (NASDAQ:MDVN) must be smiling from ear to ear, as each of these companies has been a monster winner for long-term investors. In the past 5 years alone both of these companies have gone up more than 10 times in value, leaving a comparable investment in the S&P 500 in the dust.
We Fools like to invest in stocks with a strong history of market thumping returns, so we asked our team of Motley Fool contributors to share their opinions on which one of these two companies is the better buy today.
Todd Campbell: In my view, it's Medivation that is the more intriguing of these two stocks.
Brian Feroldi: Medivation certainly looks like an interesting opportunity right now, but when forced to choose I think I'd give the slight edge to Jazz. Here's why.